Medi-Maa (Macrosalb (99mtc))

Medi-Maa is a radiopharmaceutical used in nuclear medicine to image specific organ systems and disease processes.

• Oncology imaging: enables visualization of tumor metabolism and distribution for cancer staging.
• Cardiac perfusion imaging: assesses myocardial blood flow to detect ischemia.
• Renal function imaging: evaluates kidney filtration and drainage patterns.
• Bone scintigraphy: highlights areas of increased osteoblastic activity for skeletal assessment.
• Infection imaging: helps locate sites of active infection or inflammation.

• Macrosalb is a radiolabeled compound that emits gamma photons detectable by a gamma camera. After intravenous administration, it distributes according to its molecular affinity for target tissues, where the emitted radiation provides a spatial map of physiological activity, allowing clinicians to assess organ function and disease presence.

Medi-Maa may cause transient reactions related to its radiopharmaceutical nature.

Common Side Effects

• Nausea: mild, often resolves without intervention.
• Warmth or flushing at injection site.
• Transient headache.
• Mild dizziness or light‑headedness.
• Temporary metallic taste.
• Mild fatigue.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, or anaphylaxis.
• Significant radiation‑induced tissue injury (rare with diagnostic doses).
• Severe hypotension or syncope.
• Hematologic changes: transient leukopenia or thrombocytopenia.
• Renal impairment exacerbation in susceptible patients.

Prior to administration, consider patient‑specific factors and handling requirements.

• Radiation safety: follow institutional radiation protection protocols to minimize exposure to staff and family.
• Pregnancy: avoid use in pregnant patients unless the diagnostic benefit outweighs fetal radiation risk.
• Breastfeeding: discontinue breastfeeding for an appropriate interval after dosing.
• Renal function: assess kidney function; dose adjustment may be needed in severe impairment.
• Allergic history: screen for prior reactions to radiopharmaceuticals or excipients.
• Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Medi-Maa may interact with other agents that affect biodistribution or radiation exposure.

Major Interactions (Avoid)

• Concurrent administration of other radiopharmaceuticals: may cause overlapping radiation fields.
• High‑dose iodinated contrast agents: can alter tracer uptake in certain studies.

Moderate Interactions (Monitor Closely)

• Drugs affecting renal clearance (e.g., diuretics, ACE inhibitors): may modify tracer elimination.
• Thyroid‑affecting medications (e.g., amiodarone): could influence thyroid‑targeted tracers.
• Chemotherapeutic agents: may change tumor uptake patterns.
• Antihistamines or steroids: could mask mild allergic reactions.
• Beta‑blockers: may affect cardiac perfusion imaging results.